Table 1

Baseline characteristics of the patients

CharacteristicsTreatment group
FIN-RACo+infliximab (n=50)FIN-RACo+placebo (n=49)
Demographics
 Female/male, n35/1531/18
 Age years, mean (SD)47 (10)46 (11)
 Duration of symptoms (months), median (IQR)4 (2, 6)4 (3, 6)
 Rheumatoid factor present, n (%)39 (78)36 (73)
Measures of disease activity
 DAS28, mean (SD)5.5 (1.0)5.6 (1.4)
 Erythrocyte sedimentation rate (mm/h), mean (SD)34 (22)32 (23)
 Serum C-reactive protein (mg/l), mean (SD)25 (29)36 (44)
 Number of swollen joints, mean (SD)15 (5)16 (8)
 Number of tender joints, mean (SD)19 (9)21 (11)
 Patient's global assessment (VAS), mean (SD)50 (24)48 (27)
 Physician's global assessment (VAS), mean (SD)49 (21)54 (20)
 Physical function (HAQ), mean (SD)1.1 (0.6)0.9 (0.7)
 Early morning stiffness (min), median (IQR)120 (60, 180)120 (60, 180)
Radiography
 Erosion score*, mean (SD)2.4 (6.7)1.7 (4.2)
 Narrowing score*, mean (SD)0.4 (1.5)0.3 (0.6)
 Total score*, mean (SD)2.8 (7.8)2.0 (4.5)
 Erosions in hand or foot radiographs, n (%)22 (44)15 (31)
  • *Radiologic score by modified Sharp-van der Heijde score.

  • DAS28, 28-joint disease activity score; HAQ, Health Assessment Questionnaire; n, number of patients; VAS, visual analogue scale.